KK2223 / Kyowa Kirin - LARVOL DELTA

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Kyowa Kirin, Inc.

First-in-human • New P1 trial • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma